ArticleBMC cancer2021

Effectiveness and safety of pegylated liposomal doxorubicin versus epirubicin as neoadjuvant or adjuvant chemotherapy for breast cancer: a real-world study.

Jin Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.